Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes’ Bow

The endocannabinoid system has recently emerged as an important modulator of several functions of adipose tissue, including cell proliferation, differentiation and secretion. Here, we will review the effects of cannabinoid type 1 (CB1) receptor activation/blockade in adipocytes by summarising the data in the literature since the discovery of the presence of this receptor in adipose tissue. We will also discuss our original data obtained in mouse 3T3‐L1 adipocyte cells using WIN55 212, a CB1/CB2 receptor agonist and SR141716 (rimonabant), a specific CB1 receptor antagonist, respectively, in different experimental settings.

[1]  G. Wittert,et al.  The expression of receptors for endocannabinoids in human and rodent skeletal muscle. , 2007, Biochemical and biophysical research communications.

[2]  P. Bernante,et al.  The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  P. Löfgren,et al.  Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  V. Marzo,et al.  Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.

[5]  V. Marzo,et al.  Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men , 2007, International Journal of Obesity.

[6]  F. Fezza,et al.  Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. , 2006, Biochimie.

[7]  M. Jensen,et al.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study , 2006, The Lancet.

[8]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[9]  M. Miyazaki,et al.  Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis Published, JLR Papers in Press, June 2, 2006. , 2006, Journal of Lipid Research.

[10]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  J. Bełtowski.  Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[12]  J. Klein,et al.  Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[13]  M. Laakso,et al.  Visfatin is an adipokine, but it is not regulated by thiazolidinediones. , 2006, The Journal of clinical endocrinology and metabolism.

[14]  F. Fezza,et al.  New insights into endocannabinoid degradation and its therapeutic potential. , 2006, Mini reviews in medicinal chemistry.

[15]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[16]  F. Rodríguez de Fonseca,et al.  Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. , 2006, European journal of pharmacology.

[17]  F. Bermúdez-Silva,et al.  Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell , 2006 .

[18]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[19]  B. Scatton,et al.  The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics , 2022 .

[20]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[21]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[22]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[23]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[24]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[25]  P. Soubrié,et al.  The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  A. Davenport,et al.  Emerging roles of apelin in biology and medicine. , 2005, Pharmacology & therapeutics.

[27]  M. Matsuda,et al.  Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. , 2005, Science.

[28]  P. Casellas,et al.  Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. , 2005, European journal of pharmacology.

[29]  C. Darimont,et al.  C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. , 2005, Diabetes.

[30]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[31]  T. Kadowaki,et al.  Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.

[32]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[33]  I. Castan-Laurell,et al.  Apelin, a newly identified adipokine up-regulated by insulin and obesity. , 2005, Endocrinology.

[34]  M. Matsuda,et al.  Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin , 2005, Science.

[35]  D. Thompson,et al.  Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin , 2004, The Journal of Neuroscience.

[36]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[37]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[38]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[39]  R. Mooney,et al.  Interleukin-6 induces cellular insulin resistance in hepatocytes. , 2002, Diabetes.

[40]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[41]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[42]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[43]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[44]  S. Kersten.  Mechanisms of nutritional and hormonal regulation of lipogenesis , 2001, EMBO reports.

[45]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Bruckert,et al.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. , 2000, The Journal of clinical endocrinology and metabolism.

[47]  S. Hinuma,et al.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. , 1998, Biochemical and biophysical research communications.

[48]  A. Greenberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Omental and Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: Depot Difference and Regulation by Glucocorticoid* , 1997 .

[49]  E. Hell,et al.  Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. , 1997, Journal of lipid research.

[50]  Y. Nakano,et al.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. , 1996, Journal of biochemistry.

[51]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[52]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[53]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[54]  H. Heng,et al.  A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. , 1993, Gene.

[55]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[56]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[57]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Shyi-Jang Shin,et al.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[59]  P. Kern,et al.  Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. , 2006, American journal of physiology. Endocrinology and metabolism.

[60]  F. Fezza,et al.  Endocannabinoids in adipocytes during differentiation and their role in glucose uptake , 2006, Cellular and Molecular Life Sciences.

[61]  B. Scatton,et al.  The Cannabinoid CB 1 Receptor Antagonist Rimonabant ( SR 141716 ) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3 T 3 F 442 A Preadipocytes , 2006 .

[62]  M. J. Charron,et al.  Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. , 1999, Diabetes.